Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BENLYSTA safely and effectively. See full prescribing information for BENLYSTA. BENLYSTA (belimumab) for injection, for intravenous useBENLYSTA (belimumab) injection, for subcutaneous useInitial U.S. Approval: 2011
Medication labelWhy this: Advisory · dailymed-prescription
BENLYSTA is indicated for the treatment of patients 5 years of age and older with: •Active systemic lupus erythematosus (SLE) who are receiving standard therapy, and •Active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system (CNS) lupus. Use of BENLYSTA is not recommended in this situation.
- generic_name
- belimumab
- product_names
- belimumab
- ndc
- 49401-102, 49401-102-01, 49401-101, 49401-101-01, 49401-088, 49401-088-42, 49401-088-47, 49401-088-50, 49401-088-01, 49401-088-35, 49401-088-02, 49401-088-61
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en